[{"id":"31d6ffe2-4ba8-4867-90e7-d162923e570c","acronym":"Lung-MAP","url":"https://clinicaltrials.gov/study/NCT02154490","created_at":"2021-01-18T06:59:07.141Z","updated_at":"2024-07-02T16:35:46.669Z","phase":"","brief_title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","source_id_and_acronym":"NCT02154490 - Lung-MAP","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • ALK • EML4 • TP63","pipe":" | ","alterations":" EGFR mutation • ALK fusion • TTF1 negative","tags":["EGFR • ALK • EML4 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • TTF1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 1864","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/15/2022","study_completion_date":" 04/15/2022","last_update_posted":"2023-06-01"},{"id":"925965e4-64ba-4c5e-b68a-d4af842d4a0c","acronym":"SQUINT","url":"https://clinicaltrials.gov/study/NCT03823625","created_at":"2021-01-18T18:53:12.046Z","updated_at":"2024-07-02T16:36:47.632Z","phase":"Phase 2","brief_title":"An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)","source_id_and_acronym":"NCT03823625 - SQUINT","lead_sponsor":"Fondazione Ricerca Traslazionale","biomarkers":" PD-L1 • NKX2-1 • TP63","pipe":" | ","alterations":" PD-L1 expression • TTF1 negative","tags":["PD-L1 • NKX2-1 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TTF1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 112","initiation":"Initiation: 09/13/2017","start_date":" 09/13/2017","primary_txt":" Primary completion: 02/28/2021","primary_completion_date":" 02/28/2021","study_txt":" Completion: 02/28/2021","study_completion_date":" 02/28/2021","last_update_posted":"2020-03-25"}]